Shares of the UK's Sinclair Pharma slid 13 percent after the company announced that its U.S. partner planned to delay the launch of Decapinol for gum disease in order to explore a new formulation. They hope to launch the new formulation next year. The partner, OraPharma, wants to explore adding a preservative to the product--evidently as a response to a recent J&J recall. Report